CR20230015A - Fusiones heterodiméricas de relaxina y usos de las mismas - Google Patents

Fusiones heterodiméricas de relaxina y usos de las mismas

Info

Publication number
CR20230015A
CR20230015A CR20230015A CR20230015A CR20230015A CR 20230015 A CR20230015 A CR 20230015A CR 20230015 A CR20230015 A CR 20230015A CR 20230015 A CR20230015 A CR 20230015A CR 20230015 A CR20230015 A CR 20230015A
Authority
CR
Costa Rica
Prior art keywords
relaxin
heterodimeric
treatment
fusions
fusion polypeptides
Prior art date
Application number
CR20230015A
Other languages
English (en)
Inventor
Isabelle Sermadiras
Monika Anna Papworth
Judy Christiane Paterson
Peng Ke
Esther Marie Martin
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of CR20230015A publication Critical patent/CR20230015A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a polipéptidos de fusión heterodiméricos de Relaxina, en particular, a polipéptidos de fusión heterodiméricos de Relaxina 2 y a usos de los mismos. Por tanto, la invención proporciona polipéptidos de fusión de Relaxina, moléculas de ácido nucleico, vectores, células hospedadoras, composiciones farmacéuticas y kits que comprenden los mismos y usos de los mismos, incluyendo métodos de tratamiento. Los polipéptidos y las composiciones de la invención pueden ser útiles, en particular, en el tratamiento de enfermedades cardiovasculares, por ejemplo, para el tratamiento de la insuficiencia cardíaca.<br /> <br />
CR20230015A 2020-06-17 2021-06-16 Fusiones heterodiméricas de relaxina y usos de las mismas CR20230015A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063040250P 2020-06-17 2020-06-17
PCT/EP2021/066309 WO2021255127A1 (en) 2020-06-17 2021-06-16 Heterodimeric relaxin fusions and uses thereof

Publications (1)

Publication Number Publication Date
CR20230015A true CR20230015A (es) 2023-02-17

Family

ID=76584509

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230015A CR20230015A (es) 2020-06-17 2021-06-16 Fusiones heterodiméricas de relaxina y usos de las mismas

Country Status (17)

Country Link
US (2) US11795205B2 (es)
EP (1) EP4168434A1 (es)
JP (1) JP2023530335A (es)
KR (1) KR20230024994A (es)
CN (1) CN115916813A (es)
AR (1) AR125007A1 (es)
AU (2) AU2021290997C1 (es)
BR (1) BR112022025019A2 (es)
CA (1) CA3186143A1 (es)
CL (1) CL2022003578A1 (es)
CO (1) CO2023000038A2 (es)
CR (1) CR20230015A (es)
EC (1) ECSP23002960A (es)
IL (1) IL298786A (es)
MX (1) MX2022016340A (es)
TW (1) TW202214673A (es)
WO (1) WO2021255127A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024015634A2 (en) * 2022-07-15 2024-01-18 Nutcracker Therapeutics, Inc. Mrna therapies including sirp-alpha
WO2024121362A1 (en) 2022-12-09 2024-06-13 Astrazeneca Ab Dosing regimens using heterodimeric relaxin fusions
WO2024184206A1 (en) 2023-03-03 2024-09-12 Astrazeneca Ab Pharmaceutical formulation comprising heterodimeric relaxin fusion proteins and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US8389475B2 (en) * 2009-08-10 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Relaxin analogs
AU2011325833C1 (en) * 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
KR20140054009A (ko) * 2011-07-01 2014-05-08 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신 융합 폴리펩타이드 및 그의 용도
AR094147A1 (es) 2012-12-27 2015-07-15 Bayer Pharma Aktiengellschaft Polipeptidos de fusion con actividad de relaxina y sus usos
EP3107938B1 (en) * 2014-05-28 2022-05-04 Zymeworks Inc. Modified antigen binding polypeptide constructs and uses thereof
JP2020505029A (ja) * 2017-01-25 2020-02-20 メディミューン，エルエルシー リラキシン融合ポリペプチドおよびその使用

Also Published As

Publication number Publication date
KR20230024994A (ko) 2023-02-21
BR112022025019A2 (pt) 2022-12-27
US20220017591A1 (en) 2022-01-20
MX2022016340A (es) 2023-01-24
TW202214673A (zh) 2022-04-16
CL2022003578A1 (es) 2023-06-09
AU2021290997C1 (en) 2024-01-04
ECSP23002960A (es) 2023-03-31
JP2023530335A (ja) 2023-07-14
CN115916813A (zh) 2023-04-04
IL298786A (en) 2023-02-01
AU2021290997B2 (en) 2023-10-12
US11795205B2 (en) 2023-10-24
WO2021255127A1 (en) 2021-12-23
AR125007A1 (es) 2023-05-31
CA3186143A1 (en) 2021-12-23
CO2023000038A2 (es) 2023-01-16
AU2021290997A1 (en) 2023-02-09
AU2024200074A1 (en) 2024-01-25
US20240025958A1 (en) 2024-01-25
EP4168434A1 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
MX2022016340A (es) Fusiones heterodimericas de relaxina y usos de las mismas.
MX2020009514A (es) Anticuerpos anti-claudina 18.2 (cldn18.2).
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
MX2011008094A (es) Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
TNSN08064A1 (en) Albumin fusion proteins
PH12020551907A1 (en) Antagonizing cd73 antibody
DK0559884T4 (da) Rekombinante virusvektorer til ekspression i muskelceller
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
DE60336228D1 (de) Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden
WO2005003296A3 (en) Albumin fusion proteins
WO2007010401A3 (en) Glycosylated il-7, preparation and uses
AR076541A1 (es) Mutantes de fgf21 y usos del mismo
CL2011003121A1 (es) Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso.
MEP53308A (en) Novel peptides that bind to the erythropoietin receptor
WO2022256499A3 (en) Bcma targeting trispecific proteins and methods of use
ZA202304098B (en) Il-2 mutants and application thereof
MX2023009737A (es) Proteínas de fusion y constructos de acidos nucleicos.
MX2022016389A (es) Conjugados de citocina.
WO2016048999A3 (en) Fgf21 truncations and mutants and uses thereof
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.
EP3239168B1 (en) Derivative of conotoxin peptide kappa-cptx-btl02, preparation method therefor, and uses thereof
BR112022021635A2 (pt) Distrofinas miniaturizadas tendo domínios de fusão de espectrina e usos das mesmas
WO2022219075A3 (en) Peptides, nanovesicles, and uses thereof for drug delivery
CN107001433B (zh) 芋螺毒素肽κ-CPTx-btl03、其制备方法及应用
BR112019004337A2 (pt) peptídeo isolado, polipeptídeo isolado, método para modificar um peptídeo, ácido nucleico isolado, construção genética, célula, métodos produção de um agente, de promoção de proliferação celular e de cicatrizar de uma ferida, agente, composição farmacêuticae anticorpo